Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1974

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Restovar, a new combined oral contraceptive with a low estrogen content.

[Restovar un nouveau contraceptif oral combine a faible teneur en

oestrogene.]

AUTHORS

Fondu F; Lowijck J

SOURCE

(Restovar, a new method combined oral contraceptive with a low estrogen

content) Bruxelles-Medical 54(8): 453-458. August 1974.

ABSTRACT

A new oral contraceptive, Restovar (.0375 mg ethinyl estradiol and .75 mg lynestrenol, combined) was taken by 96

Belgian women for 1103 cycles. There were no pregnancies despite 6 incidents of forgotten pills. The latent period

was 2.3 days in 94% of cycles; the cycle length was 27-29 days in 97%; the duration of withdrawal bleeding occurred

in .5% and spotting in 6.8% of cycles. The most common side effects were nausea (2% of cycles), breast pain

(2.6%), leukorrhea (2.4%), and heaviness in the legs (1.9%). Side effects reported to be less frequent, usually than

with the previous pill, were headaches improved in 5.4%, and libido increased in 1.2%. There were 11 unrelated and

5 drug related drop-outs. (PubHealth.info Document ID: CONT7T 3513-06)

PubHealth.info NOTE: The author(s) of this article titled, "Restovar, a new combined oral contraceptive with a low

estrogen content. [Restovar un nouveau contraceptif oral combine a faible teneur en oestrogene.]", is(are) Fondu F;

Lowijck J. The source of this article is "(Restovar, a new method combined oral contraceptive with a low estrogen

content) Bruxelles-Medical 54(8): 453-458. August 1974.". This article was published in 1974 in French language(s).

(PubHealth.info® Document ID: CONT7T 3513-06. All rights reserved with PubHealth.info) PIN: 33513

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.